Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity

Vaccine

Volumn 28, Issue 18, 2010, Pages 3247-3256

  Machado, Alexandre V ^a,b   Caetano, Bráulia C ^a,b,c   Barbosa, Rafael P ^a,b   Salgado, Ana Paula C ^a,b   Rabelo, Renata H ^a,b   Garcia, Cristiana C ^a   Bruna Romero, Oscar ^a   Escriou, Nicolas ^d   Gazzinelli, Ricardo T ^a,b,c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d INSTITUT PASTEUR   (France)

Author keywords

Adenovirus; Influenza; Reverse genetics; SAG2; Toxoplasmosis; Vaccine

Indexed keywords

PARASITE ANTIGEN; SURFACE ANTIGEN 2; TOXOPLASMA GONDII VACCINE; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNIZATION; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXOPLASMA GONDII; TOXOPLASMOSIS; VACCINE PRODUCTION; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BRAIN; CYTOKINES; FEMALE; GENETIC VECTORS; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SPLEEN; SURVIVAL ANALYSIS; TOXOPLASMA; TOXOPLASMOSIS;

EID: 77949659658     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.003     Document Type: Article

References (70)

1. Andre F.E., Booy R., Bock H.L., Clemens J., Datta S.K., John T.J., et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bulletin of the World Health Organization 86 February (2) (2008) 140-146
2. Crampton A., and Vanniasinkam T. Parasite vaccines: the new generation. Infection, Genetics and Evolution 7 September (5) (2007) 664-673
3. Rocha C., Caetano B., Machado A., and Bruna-Romero O. Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. International Microbiology 7 2 (2004) 89-94
4. Rodrigues M.M., Boscardin S.B., Vasconcelos J.R., Hiyane M.I., Salay G., and Soares I.S. Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines. Annals of the Brazilian Academy of Sciences 75 4 (2003) 443-468
5. Bowie A.G., and Haga I.R. The role of Toll-like receptors in the host response to viruses. Molecular Immunology 42 May (8) (2005) 859-867
6. Ishii K.J., and Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. Journal of Clinical Immunology 27 July (4) (2007) 363-371
7. Ichinohe T., Iwasaki A., and Hasegawa H. Innate sensors of influenza virus: clues to developing better intranasal vaccines. Expert Review of Vaccines 7 November (9) (2008) 1435-1445
8. Wong J.P., Christopher M.E., Viswanathan S., Karpoff N., Dai X., Das D., et al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 27 May 26 (25-26) (2009) 3481-3483
9. Neumann G., Whitt M., and Kawaoka Y. A decade after the generation of a negative-sense RNA virus from cloned cDNA-what have we learned?. Journal of General Virology 83 11 (2002) 2635-2662
10. Grayson M.H., and Holtzman M.J. Emerging role of dendritic cells in respiratory viral infection. Journal of Molecular Medicine (Berlin, Germany) 85 October (10) (2007) 1057-1068
11. Gonzalez-Aseguinolaza G., Nakaya Y., Molano A., Dy E., Esteban M., Rodriguez D., et al. Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii. Journal of Virology 77 November (21) (2003) 11859-11866
12. Li S., Polonis V., Isobe H., Zaghouani H., Guinea R., Moran T., et al. Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. Journal of Virology 67 11 (1993) 6659-6666
13. Li S., Rodrigues M., Rodriguez D., Rodriguez J.R., Esteban M., Palese P., et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proceedings of the National Academy of Sciences of the United States of America 90 11 (1993) 5214-5218
14. Murata K., Garcia-Sastre A., Tsuji M., Rodrigues M., Rodriguez D., Rodriguez J.R., et al. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cellular Immunology 173 1 (1996) 96-107
15. Muster T., Ferko B., Klima A., Purtscher M., Trkola A., Schulz P., et al. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. Journal of Virology 69 11 (1995) 6678-6686
16. Ferko B., Stasakova J., Sereinig S., Romanova J., Katinger D., Niebler B., et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. Journal of Virology 75 19 (2001) 8899-8908
17. Lamb R.A., and Krug R.M. Orthomyxoviridae: the viruses and their replication. In: Fields B.N., Knipe D.M., Howley P.M., et al. (Eds). Virology. 5th ed. (2007), Lippincott-Raven, Philadelphia 1647-1690
18. Luytjes W., Krystal M., Enami M., Pavin J.D., and Palese P. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59 6 (1989) 1107-1113
19. Neumann G., Zobel A., and Hobom G. RNA polymerase I-mediated expression of influenza viral RNA molecules. Virology 202 July (1) (1994) 477-479
20. Bergmann M., and Muster T. Mutations in the nonconserved noncoding sequences of the influenza A virus segments affect viral vRNA formation. Virus Research 44 1 (1996) 23-31
21. Muster T., and Zheng H. Nonconserved nucleotides at the 3′ and 5′ ends of an influenza A virus RNA play an important role in viral RNA replication. Virus Research 44 1 (1996) 23-31
22. Zheng H., Palese P., and Garcia-Sastre A. Nonconserved nucleotides at the 3′ and 5′ ends of an influenza A virus RNA play an important role in viral RNA replication. Virology 217 (1996) 242-251
23. Marsh G.A., Rabadan R., Levine A.J., and Palese P. Highly conserved regions of influenza a virus polymerase gene segments are critical for efficient viral RNA packaging. Journal of Virology 82 March (5) (2008) 2295-2304
24. Marsh G.A., Hatami R., and Palese P. Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. Journal of Virology 81 September (18) (2007) 9727-9736
25. Fujii K., Fujii Y., Noda T., Muramoto Y., Watanabe T., Takada A., et al. Importance of both the coding and the segment-specific noncoding regions of the influenza A virus NS segment for its efficient incorporation into virions. Journal of Virology 79 6 (2005) 3766-3774
26. Fujii Y., Goto H., Watanabe T., Yoshida T., and Kawaoka Y. Selective incorporation of influenza virus RNA segments into virions. Proceedings of the National Academy of Sciences of United States of America 100 4 (2003) 2002-2007
27. Machado A., Naffakh N., van der Werf S., and Escriou N. Expression of a foreign gene by stable recombinant influenza viruses harboring a dicistronic genomic segment with an internal promoter. Virology 313 1 (2003) 235-249
28. Machado A., Naffakh N., van der Werf S., and Escriou N. Recombinant influenza A viruses harboring optimized dicistronic NA segment with an extended native 5′ terminal sequence: induction of heterospecific B and T cell responses in mice. Virology 345 1 (2006) 73-87
29. Dubey J.P., Lindsay D.S., and Speer C.A. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clinical Microbiology Reviews 11 April (2) (1998) 267-299
30. Luft B.J., and Remington J.S. Toxoplasmic encephalitis in AIDS. Clinical Infectious Disease 15 August (2) (1992) 211-222
31. Denkers E.Y., and Gazzinelli R.T. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clinical Microbiology Reviews 11 4 (1998) 569-588
32. Gigley J.P., Fox B.A., and Bzik D.J. Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication. Journal of Immunology 182 January 15 (2) (2009) 1069-1078
33. Bhopale G.M. Development of a vaccine for toxoplasmosis: current status. Microbes and Infection/Institut Pasteur 5 April (5) (2003) 457-462
34. Petersen E., Nielsen H.V., Christiansen L., and Spenter J. Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii. Vaccine 16 August (13) (1998) 1283-1289
35. Letscher-Bru V., Villard O., Risse B., Zauke M., Klein J.P., and Kien T.T. Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin-12 against toxoplasmosis in mice. Infection and Immunity 66 September (9) (1998) 4503-4506
36. Haumont M., Delhaye L., Garcia L., Jurado M., Mazzu P., Daminet V., et al. Protective immunity against congenital toxoplasmosis with recombinant SAG1 protein in a guinea pig model. Infection and Immunity 68 September (9) (2000) 4948-4953
37. Nielsen H.V., Lauemoller S.L., Christiansen L., Buus S., Fomsgaard A., and Petersen E. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Infection and Immunity 67 December (12) (1999) 6358-6363
38. Angus C.W., Klivington-Evans D., Dubey J.P., and Kovacs J.A. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. The Journal of Infectious Diseases 181 January (1) (2000) 317-324
39. Caetano B.C., Bruna-Romero O., Fux B., Mendes E.A., Penido M.L., and Gazzinelli R.T. Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of Toxoplasma gondii induces immune response and protection against infection in mice. Human Gene Therapy 17 April (4) (2006) 415-426
40. Giraldo M., Cannizzaro H., Ferguson M.A., Almeida I.C., and Gazzinelli R.T. Fractionation of membrane components from tachyzoite forms of Toxoplasma gondii: differential recognition by immunoglobulin M (IgM) and IgG present in sera from patients with acute or chronic toxoplasmosis. Journal of Clinical Microbiology 38 April (4) (2000) 1453-1460
41. Fodor E., Devenish L., Engelhardt O.G., Palese P., Brownlee G.G., and Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. Journal of Virology 73 November (11) (1999) 9679-9682
42. Bruna-Romero O., Lasarte J.J., Wilkinson G., Grace K., Clarke B., Borras-Cuesta F., et al. Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology 25 2 (1997) 470-477
43. Reed L.J., and Muench H. Simple method of estimating fifty percent end-points. The American Journal of Hygiene 27 (1938) 493-497
44. Stech J., Garn H., Wegmann M., Wagner R., and Klenk H.D. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nature Medicine 11 6 (2005) 683-689
45. Nakaya Y., Zheng H., and Garcia-Sastre A. Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants. Vaccine 21 May 16 (17-18) (2003) 2097-2106
46. Gonzalo R.M., Rodriguez D., Garcia-Sastre A., Rodriguez J.R., Palese P., and Esteban M. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants. Vaccine 17 February 26 (7-8) (1999) 887-892
47. Miyahira Y., Garcia-Sastre A., Rodriguez D., Rodriguez J.R., Murata K., Tsuji M., et al. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proceedings of the National Academy of Sciences of the United States of America 95 7 (1998) 3954-3959
48. Gherardi M.M., Najera J.L., Perez-Jimenez E., Guerra S., Garcia-Sastre A., and Esteban M. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. Journal of Virology 77 12 (2003) 7048-7057
49. Denkers E.Y., Yap G., Scharton-Kersten T., Charest H., Butcher B.A., Caspar P., et al. Perforin-mediated cytolysis plays a limited role in host resistance to Toxoplasma gondii. Journal of Immunology 159 August 15 (4) (1997) 1903-1908
50. Nakaya Y., Nakaya T., Park M.S., Cros J., Imanishi J., Palese P., et al. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors. Journal of Virology 78 September (17) (2004) 9366-9375
51. Woodland D.L. Jump-starting the immune system: prime-boosting comes of age. Trends in Immunology 25 February (2) (2004) 98-104
52. Koyama S., Ishii K.J., Kumar H., Tanimoto T., Coban C., Uematsu S., et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. Journal of Immunology 179 October 1 (7) (2007) 4711-4720
53. Wang J.P., Bowen G.N., Padden C., Cerny A., Finberg R.W., Newburger P.E., et al. Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood 112 September 1 (5) (2008) 2028-2034
54. Geeraedts F., Goutagny N., Hornung V., Severa M., de Haan A., Pool J., et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathogens 4 August (8) (2008) e1000138
55. Pothlichet J., Chignard M., and Si-Tahar M. Cutting edge: innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway. Journal of Immunology 180 February 15 (4) (2008) 2034-2038
56. Montoya J.G., and Liesenfeld O. Toxoplasmosis. Lancet 363 June 12 (9425) (2004) 1965-1976
57. D'Andrea A., Rengaraju M., Valiante N.M., Chehimi J., Kubin M., Aste M., et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. The Journal of Experimental Medicine 176 November 1 (5) (1992) 1387-1398
58. Kobayashi M., Fitz L., Ryan M., Hewick R.M., Clark S.C., Chan S., et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. The Journal of Experimental Medicine 170 September 1 (3) (1989) 827-845
59. Lang C., Gross U., and Luder C.G. Subversion of innate and adaptive immune responses by Toxoplasma gondii. Parasitology Research 100 January (2) (2007) 191-203
60. Scorza T., D'Souza S., Laloup M., Dewit J., De Braekeleer J., Verschueren H., et al. A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infection. Infection and Immunity 71 January (1) (2003) 309-316
61. Aosai F., Mun H.S., Norose K., Chen M., Hata H., Kobayashi M., et al. Protective immunity induced by vaccination with SAG1 gene-transfected cells against Toxoplasma gondii-infection in mice. Microbiology and Immunology 43 1 (1999) 87-91
62. Sayles P.C., Gibson G.W., and Johnson L.L. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infection and Immunity 68 March (3) (2000) 1026-1033
63. Kang H., Remington J.S., and Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. Journal of Immunology 164 March 1 (5) (2000) 2629-2634
64. Hegab S.M., and Al-Mutawa S.A. Immunopathogenesis of toxoplasmosis. Clinical and Experimental Medicine 3 September (2) (2003) 84-105
65. Gazzinelli R.T., and Denkers E.Y. Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nature Reviews Immunology 6 December (12) (2006) 895-906
66. Buzoni-Gatel D., Schulthess J., Menard L.C., and Kasper L.H. Mucosal defences against orally acquired protozoan parasites, emphasis on Toxoplasma gondii infections. Cellular Microbiology 8 April (4) (2006) 535-544
67. Mennechet F.J., Kasper L.H., Rachinel N., Li W., Vandewalle A., and Buzoni-Gatel D. Lamina propria CD4+ T lymphocytes synergize with murine intestinal epithelial cells to enhance proinflammatory response against an intracellular pathogen. Journal of Immunology 168 March 15 (6) (2002) 2988-2996
68. Kasper L., Courret N., Darche S., Luangsay S., Mennechet F., Minns L., et al. Toxoplasma gondii and mucosal immunity. International Journal for Parasitology 34 March 9 (3) (2004) 401-409
69. Chardes T., and Bout D. Mucosal immune response in toxoplasmosis. Research in Immunology 144 January (1) (1993) 57-60
70. Schulthess J., Fourreau D., Darche S., Meresse B., Kasper L., Cerf-Bensussan N., et al. Mucosal immunity in Toxoplasma gondii infection. Parasite (Paris, France) 15 September (3) (2008) 389-395